Efficacy of Mometasone Furoate Nasal Spray in Delayed Antibiotic Prescriptions for Acute Rhinosinusitis: A Multicenter, Randomized, Open-Label, Comparative, Prospective, Parallel Group Study
While their clinical presentation is similar, post-viral rhinosinusitis does not indicate the possible development of bacterial rhinosinusitis which occurs in only 0.5% to 5% of all cases of ARS. However, unreasonable antibacterial therapy is prescribed in 54% to 77% of cases. The perspective is to use delayed antibacterial therapy management. The purpose of the study was to investigate the efficacy of mometasone furoate nasal spray within the delayed prescription approach. Methods: A multicenter, randomized, open-label, comparative, prospective, parallel group study enrolled a total of 156 patients with ARS aged 18 to 60 years, of them 155 patients completed the study. The patients were randomized into the main group of Mometasone Furoate (Flix) Nasal Spray or into the control group of amoxicillin clavulanate tablets while both groups were administered a standard ARS therapy. Findings: The use of MF nasal spray within the delayed antibiotics prescription approach has a significantly higher efficacy compared to the immediate antibiotics prescription in the first days of treatment (p < 0.05). Antibacterial therapy was prescribed to 42.3% of patients in the main group compared to 100.0% of patients in the control group (p < 0.05). It was shown that there were statistically significant differences in the dynamics of changes in the total symptom score between the patients administered antibiotics and the antibiotic-naive patients. Conclusion: The use of MF within the delayed antibiotics prescription approach reliably improves the pattern of symptoms over time at the disease onset and significantly reduces the need for NSAIDs administration and antibiotics prescription frequency.
References
[1]
Fokkens, W.J., Lund, V.J., Hopkins, C., Hellings, P.W., Kern, R., Reitsma, S., et al. (2020) European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology, 58, 1-464. https://doi.org/10.4193/Rhin20.600
[2]
Jaume, F., Valls-Mateus, M. and Mullol, J. (2020) Common Cold and Acute Rhinosinusitis: Up-to-Date Management in 2020. Current Allergy and Asthma Reports, 20, Article No. 28. https://doi.org/10.1007/s11882-020-00917-5
[3]
Fokkens, W., Lund, V., Bachert, C., Clement, P., Helllings, P., Holmstrom, M., et al. (2005) EAACI Position Paper on Rhinosinusitis and Nasal Polyps Executive Summary. Allergy, 60, 583-601. https://doi.org/10.1111/j.1398-9995.2005.00830.x
[4]
Pasternak, G., Lewandowicz-Uszyńska, A. and Królak-Olejnik, B. (2020) Nawracające zakażenia dróg oddechowych u dzieci. Polski MerkuriuszLekarski, 49, 260-266.
[5]
Hoffmans, R., Wagemakers, A., van Drunen, C., Hellings, P. and Fokkens, W. (2018) Acute and Chronic Rhinosinusitis and Allergic Rhinitis in Relation to Comorbidity, Ethnicity and Environment. PLOS ONE, 13, e0192330. https://doi.org/10.1371/journal.pone.0192330
[6]
Smith, S.S., Ference, E.H., Evans, C.T., Tan, B.K., Kern, R.C. and Chandra, R.K. (2014) The Prevalence of Bacterial Infection in Acute Rhinosinusitis: A Systematic Review and Meta‐Analysis. The Laryngoscope, 125, 57-69. https://doi.org/10.1002/lary.24709
[7]
Lemiengre, M.B., van Driel, M.L., Merenstein, D., Liira, H., Mäkelä, M. and De Sutter, A.I. (2018) Antibiotics for Acute Rhinosinusitis in Adults. Cochrane Database of Systematic Reviews, No. 9, CD006089. https://doi.org/10.1002/14651858.cd006089.pub5
[8]
McCullough, A.R., Pollack, A.J., Plejdrup Hansen, M., Glasziou, P.P., Looke, D.F., Britt, H.C., et al. (2017) Antibiotics for Acute Respiratory Infections in General Practice: Comparison of Prescribing Rates with Guideline Recommendations. Medical Journal of Australia, 207, 65-69. https://doi.org/10.5694/mja16.01042
[9]
Poss-Doering, R., Kronsteiner, D., Kamradt, M., Andres, E., Kaufmann-Kolle, P., Wensing, M., et al. (2021) Antibiotic Prescribing for Acute, Non-Complicated Infections in Primary Care in Germany: Baseline Assessment in the Cluster Randomized Trial Arena. BMC Infectious Diseases, 21, Article No. 877. https://doi.org/10.1186/s12879-021-06571-0
[10]
Antimicrobial Resistance Collaborators (2022) Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. The Lancet, 399, 629-655.
[11]
Shekhar, S. and Petersen, F.C. (2020) The Dark Side of Antibiotics: Adverse Effects on the Infant Immune Defense against Infection. Frontiers in Pediatrics, 8, Article 544460. https://doi.org/10.3389/fped.2020.544460
[12]
Spurling, G.K.P. and Del Mar, C.B. (2003) Delayed Antibiotics for Respiratory Infections. Cochrane Database of Systematic Reviews, No. 4, CD004417. https://doi.org/10.1002/14651858.CD004417
[13]
Spurling, G.K., Del Mar, C.B., Dooley, L., Clark, J. and Askew, D.A. (2017) Delayed Antibiotic Prescriptions for Respiratory Infections. Cochrane Database of Systematic Reviews, No. 9, CD004417. https://doi.org/10.1002/14651858.cd004417.pub5
[14]
Popovich, V.I. and Koshel, I.V. (2017) Sinupret® as Add-on Therapy to Saline Irrigation for Children with Acute Post-Viral Rhinosinusitis. Clinical Phytoscience, 3, Article No. 10. https://doi.org/10.1186/s40816-017-0047-6
[15]
Jiang, M., Chen, J., Ding, Y., Gan, C., Hou, Y., Lei, J., et al. (2021) Efficacy and Safety of Sea Salt-Derived Physiological Saline Nasal Spray as Add-on Therapy in Patients with Acute Upper Respiratory Infection: A Multicenter Retrospective Cohort Study. Medical Science Monitor, 27, e929714. https://doi.org/10.12659/msm.929714
[16]
Popovych, V.I., Beketova, H.V., Koshel, I.V., Tsodikova, O.A., Kriuchko, T.A., Abaturov, A.E., et al. (2020) An Open-Label, Multicentre, Randomized Comparative Study of Efficacy, Safety and Tolerability of the 5 Plant-Extract BNO 1012 in the Delayed Antibiotic Prescription Method in Children, Aged 6 to 11 Years with Acute Viral and Post-Viral Rhinosinusitis. American Journal of Otolaryngology, 41, Article 102564. https://doi.org/10.1016/j.amjoto.2020.102564
[17]
Popovych, V.I., Koshel, I.V., Piletska, L.I. and Orlovska, R.M. (2024) Multicenter, Randomized, Open-Label, Comparative Study of the Effectiveness of Nasal Spray Aqua Maris Extra Strong as a Symptomatic Therapy in the Technology of Delayed Antibiotic Prescription in the Treatment of Acute Rhinosinusitis in Children Aged 6-11 Years. American Journal of Otolaryngology, 45, Article 103644. https://doi.org/10.1016/j.amjoto.2022.103644
[18]
Bachert, C. and Meltzer, E.O. (2007) Effect of Mometasone Furoate Nasal Spray on Quality of Life of Patients with Acute Rhinosinusitis. Rhinology, 45, 190-196.
[19]
Meltzer, E.O., Gates, D. and Bachert, C. (2012) Mometasone Furoate Nasal Spray Increases the Number of Minimal-Symptom Days in Patients with Acute Rhinosinusitis. Annals of Allergy, Asthma & Immunology, 108, 275-279. https://doi.org/10.1016/j.anai.2012.01.015
[20]
Passali, D., Spinosi, M.C., Crisanti, A. and Bellussi, L.M. (2016) Mometasone Furoate Nasal Spray: A Systematic Review. Multidisciplinary Respiratory Medicine, 11, Article No. 18. https://doi.org/10.1186/s40248-016-0054-3
[21]
Unified Clinical Protocol of Primary, Secondary (Specilised) and Tertiary (Highly-Specialised) Medical Assistance “Acute Rhinosinusitis”. https://www.dec.gov.ua/wp-content/uploads/2019/11/2016_85_ykpmd_grs.pdf
[22]
Meltzer, E., Bachert, C. and Staudinger, H. (2005) Treating Acute Rhinosinusitis: Comparing Efficacy and Safety of Mometasone Furoate Nasal Spray, Amoxicillin, and Placebo. Journal of Allergy and Clinical Immunology, 116, 1289-1295. https://doi.org/10.1016/j.jaci.2005.08.044
[23]
Lindbaek, M. (2006) Mometasone Furoate Nasal Spray Was More Effective for Symptom Relief of Acute Rhinosinusitis than Amoxicillin or Placebo. Evidence-Based Medicine, 11, 114. https://doi.org/10.1136/ebm.11.4.114
[24]
Svensson, J., Lundberg, J., Olsson, P., Stjärne, P. and Tennvall, G.R. (2012) Cost-Effectiveness of Mometasone Furoate Nasal Spray in the Treatment of Acute Rhinosinusitis. Primary Care Respiratory Journal, 21, 412-418. https://doi.org/10.4104/pcrj.2012.00085
